BioMarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

64.67USD
1 Aug 2013
Price Change (% chg)

$0.02 (+0.03%)
Prev Close
$64.65
Open
$64.65
Day's High
$65.14
Day's Low
$63.98
Volume
258,404
Avg. Vol
442,077
52-wk High
$71.56
52-wk Low
$36.30

BMRN.OQ

Chart for BMRN.OQ

About

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company’s product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochlor... (more)

Overall

Beta: 1.20
Market Cap (Mil.): $9,057.83
Shares Outstanding (Mil.): 140.11
Dividend: --
Yield (%): --

Financials

  BMRN.OQ Industry Sector
P/E (TTM): -- 37.93 37.76
EPS (TTM): -0.93 -- --
ROI: -8.34 19.48 18.76
ROE: -10.60 20.17 19.59
Search Stocks

Niche drugmaker ViroPharma attracts takeover interest: sources

NEW YORK - ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.

19 Jun 2013

CORRECTED-UPDATE 1-Niche drugmaker ViroPharma attracts takeover interest - sources

(In June 17 item, corrects in 3rd paragraph to show that ViroPharma is 19 years old)

19 Jun 2013

UPDATE 1-Niche drugmaker ViroPharma attracts takeover interest -sources

NEW YORK, June 17 - ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.

17 Jun 2013

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $93.77 +0.27
Pfizer Inc. (PFE.N) $29.11 -0.12
Novartis AG (NOVN.VX) CHF66.60 +0.35
Merck & Co., Inc. (MRK.N) $48.58 +0.41
Roche Holding Ltd. (ROG.VX) CHF228.00 -3.50
Abbott Laboratories (ABT.N) $36.84 +0.21
Bayer AG (BAYGn.DE) €89.43 +2.08
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.85 -3.32
Eli Lilly & Co. (LLY.N) $53.50 +0.39

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks